

J & J Innovation to offer new solutions to fight cancer

14 June 2018 | News

Up to three innovators with the best idea, technology, or solution across pharmaceuticals, consumer, medical devices, global public health, and/or health technologies will be awarded up to US\$750,000



Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd., launched the Shanghai Lung Cancer Innovation QuickFire Challenge to identify new solutions for lung health and to fight lung cancer in China and around the world.

The Shanghai Lung Cancer Innovation QuickFire Challenge seeks to identify cutting-edge, early-stage innovation from around the world that addresses all stages of lung health. The competition will be open to entrepreneurs, academicians, biotech researchers and start-up companies from around the world with innovative ideas that have the potential to prevent, intercept or cure lung cancer, improving the health and well-being of millions of people in China and around the world.

Up to three innovators with the best idea, technology, or solution across pharmaceuticals, consumer, medical devices, global public health, and/or health technologies will be awarded up to US\$750,000 (approximately RMB4,775,850) in total grants; one-year of residency at JLABS @ Shanghai, including a laboratory bench, workstation and access to the JLABS community; and mentorship and coaching from Johnson & Johnson Innovation, the Janssen Pharmaceutical Companies of Johnson & Johnson, and/or affiliate experts. The winners will be announced in Spring 2019 at the grand opening of the JLABS @ Shanghai in Shanghai, China.

The QuickFire Challenge welcomes submissions from June 14 to September 14, 2018. For more information about the Shanghai Lung Cancer Innovation QuickFire Challenge (including the terms and conditions of entry), please visit: <http://jllabs.tv/lungs>